[1] DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994; 13:1341-1356

[2] Jennison C, Turnbull BW. Group Sequential Tests with Applications to Clinical Trials. Boca Raton: Chapman and Hall/CRC; 2000

[3] Shah PL, Slebos D-J, Cardoso PFG, Cetti E, Voelker K, Levine B, et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomized, sham-controlled, multicentre trial. Lancet. 2011; 378: 997-1005.

[4] Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, et al. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol. 2015; 26(12):2464-9.

[5] Jansen JO, Pallmann P, MacLennan G, Campbell MK, and UK-REBOA Trial Investigators. Bayesian clinical trial designs: Another option for trauma trials? J Trauma Acute Care Surg. 2017; 83(4): 736-741

[6] Berry DA. Interim Analysis in Clinical Trials: The Role of the Likelihood Principle. Am Stat. 1987; 41(2): 117-122

[7] Berger JO, Wolpert RL. The Likelihood Principle. Hayward, California: Institute of Mathematical Statistics; 1984

[8] Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics. 2004; 60: 418-426

[9] Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J Royal Stat Soc A. 1994; 157(3): 357-416.

[10] Rosner GL, Berry DA. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat Med. 1995; 14(14): 381–394

[11] Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, Florida: CRC Press; 2011

[12] Simon R. Problems of multiplicity in clinical trials. J Stat Plan Inf. 1994; 42:209-221

[13] Freedman LS, Spiegelhalter DJ. Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials. Control Clin Trials. 1989; 10: 357-367

[14] Cox DR, Hinkely DV. Theoretical Statistics. London: Chapman & Hall; 1974. p45-46

[15] U.S. Food and Drug Administration. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. Food and Drug Administration, Rockville, MD, 2010 Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials. Accessed 16 March, 2019.

[16] U.S. Food and Drug Administration. Draft Guidance for Industry: Adaptive Designs for Clinical Trials of Drugs and Biologics. Food and Drug Administration, Rockville, MD, 2018. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics. Accessed 16 July, 2019

[17] Connor JT, Elm JJ, Broglio KR; ESETT and ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013; 66: S130-S137.

[18] Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018; 378: 11-21

[19] Broglio KR, Connor JT, Berry SM. Not too big, not too small: a goldilocks approach to sample size selection. J Biopharm Stat. 2014; 24(3): 685-705.

[20] Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc. 2017; 112(517): 11–23.

[21] Zhu H, Yu Q. A Bayesian sequential design using alpha spending function to control type I error. Stat Methods Med Res. 2017; 26(5): 2184–2196

[22] Shi H, Yin G. Control of Type I Error Rates in Bayesian Sequential Designs. Bayesian Analysis. 2019; 14(2):399-425

[23] Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012; 379: 229–35

[24] Fixed and Adaptive Clinical Trial Simulator (FACTS). Version 6.2. 2018 Berry Consultants, Austin TX.

[25] Dmitrienko A, Wang M-D. Bayesian predictive approach to interim monitoring in clinical trials. Stat Med. 2006; 25: 2178-2195.

[26] Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley & Sons Ltd; 2004.

[27] Togo K, Iwasaki M. Optimal timing for interim analyses in clinical trials. J Biopharm Stat. 2013; 23(5): 1067-80.

[28] Wu X, Xu Y, Carlin BP. Optimizing interim analysis timing for Bayesian adaptive commensurate designs. Preprint at https://arxiv.org/abs/1905.07456 (2019)

[29] Kruske J. Goals, Power and Sample size. In: Doing Bayesian Data Analysis: A Tutorial Introduction with R and Bugs. Oxford: Elsevier; 2011. p. 320-321

[30] McShane BB, Gal D, Gelman A, Robert C, Tackett JL. Abandon statistical significance. Preprint at https://arxiv.org/abs/1709.07588 (2018).

[31] Amrhein V, Greenland S, McShane B. Retire statistical significance. Nature. 2019; 567: 305-307

[32] Berry DA. A case for Bayesianism in clinical trials. Stat Med. 1993; 12: 1377-1393

[33] Harrell F. p-values and Type I Errors are Not the Probabilities We Need. https://www.fharrell.com/post/pvalprobs/ (2019). Accessed 18 June 2019

[34] Müller P, Berry DA, Grieve AP, Smith M, Krams M. Simulation-based sequential Bayesian design. J Stat Plan Inf. 2007; 137(1): 3140–3150

[35] Berry DA, Müller P, Grieve AP, Smith M, Parke T, Blazek R, et al. Adaptive Bayesian designs for dose-ranging drug trials. In: West M, Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M, editors. Case Studies in Bayesian Statistics. Volume V. New York: Springer; 2001. p99-181.

[36] Spiegelhalter DS, Freedman LS. Bayesian approaches to clinical trials. In: Bernardo JM, DeGrout MH, Lindley DV, Smith AFM, editors. Bayesian Statistics 3, Oxford: Oxford University Press; 1988. p453-477